Moderna’s New Deal: Is This a Case of ‘Sell the News’?
When Moderna announced a new deal with the U.S. government for its COVID-19 vaccine, it appeared be a case of “sell the news,” because this is ultimately a net positive for the company.
When Moderna announced a new deal with the U.S. government for its COVID-19 vaccine, it appeared be a case of “sell the news,” because this is ultimately a net positive for the company.
Royalty Pharma reported quarterly results on Wednesday morning that were boosted by Imbruvica and the addition of new royalties.
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Eyenovia shares soared on Tuesday after the company announced an exclusive license agreement with Artic Vision.
24/7 Wall St. has compiled a list of some speculative biotech plays that could see gains of up to 300% in the coming months.
Seres Therapeutics shares more than tripled early on Monday after the firm announced positive late-stage results for its C. difficile infection study.
AnPac Bio-Medical Science shares surged higher on Friday after the company reaffirmed its status as a COVID-19 stock.
The world may be focused on COVID-19 this year, but the battle against Alzheimer’s disease continues with no effective treatments. Biogen hopes to remedy that unfortunate situation.
Denali Therapeutics announced early Thursday that it would be progressing its Parkinson’s treatment into late-stage studies in collaboration with Biogen.
Novavax shares hit another all-time high on Wednesday after the company announced positive results from its early stage COVID-19 vaccine study.
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may be inexpensive…
Pharmacy and health insurer CVS handily beat expected earnings and revenue estimates for the second quarter.
Regeneron Pharmaceuticals, one of the front-runners for the development of a COVID-19 treatment, released an update on its antibody drug combination on Monday.
Alterity Therapeutics stock more than doubled on Tuesday after the company announced new data for its lead drug candidate for the treatment of multiple system atrophy.
Amarin reported its latest quarterly results on Tuesday morning and gave an update on the most recent developments with its blockbuster drug Vascepa.